HBRM Herborium Group Inc (PK)

Herborium Group, Inc. (OTC BB: HBRM), a botanical therapeutics� company that develops, licenses and markets novel botanical ingredients based medicinal products and related digital support content, today announced that it has entered into a purchase agreement with USA AH, a privately held Arizona based company, to acquire the proprietary formula for AcnEase�. AcnEase� (www.acnease.com) is a proprietary herbal formula based on principles of Traditional Chinese Medicine (TCM) and a modern herbaceutical science that is used for improving conditions associated with Acne and Rosacea. Herborium currently holds an exclusive license for the distribution of AcnEase� that it sells in the United States, United Kingdom and the Continental Europe. The terms of the agreement include both equity and capital that is being raised through Southridge Investment Group LLC. Upon completion of the transfer of the formula, expected before the end of 2008, Herborium will take over the manufacturing process for AcnEase� being performed in the USA eliminating the licensing fee and significantly decreasing the cost of goods (cog). Dr. Agnes Olszewski CEO of Herborium stated �With over 50 million individuals suffering from acne symptoms in the United State alone, the market potential for AcnEase� is very attractive. Purchasing of the formula will improve both our profit margin and facilitate access to wholesale distribution channels, and improvement in penetration of retail sectors. Ownership of the AcnEase� formula will also enable performance of confirmatory clinical studies in the USA that will further validate the formula�s performance and support our marketing efforts.� In addition, the company announced it has hired Dr. Aihua Qi as Vice President of TCM Research. Dr. Qi is the originator of the AcnEase� formula and will assist Herborium in improvements of the formula, identification and qualification of new products to compliment the existing pipeline. About Herborium Group, Inc. Herborium Group, Inc., a botanical therapeutics� company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk,�ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women�s Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. Certain matters discussed in this press release are �forward-looking statements� intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company�s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company�s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company�s control. The factors discussed herein and expressed from time to time in the Company�s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company�s filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.